ASCO updates NSCLC treatment guidelines

The American Society of Clinical Oncology published new guidelines for treating advanced non-small cell lung cancer (NSCLC). The recommendations incorporate greater use of targeted therapies than prior guidelines from 2011.

The new guidelines, published in the Journal of Clinical Oncology, differentiate recommended treatments by mutation status. ASCO's recommended first-line therapies in patients with EGFR-sensitizing mutations are Gilotrif afatinib from Boehringer Ingelheim GmbH (Ingelheim, Germany); Tarceva erlotinib from the Genentech unit of Roche (SIX:ROG; OTCQX:RHHBY) and Astellas Pharma Inc. (Tokyo:4503); and Iressa gefitinib from AstraZeneca plc (LSE:AZN; NYSE:AZN). ...